Laymen's summary:
Treatment-resistant schizophrenia (TRS), marked by inadequate responses to antipsychotic medications, remains a complex challenge. Recently a genome-wide association study (GWAS) revealed a polygenic architecture without specific loci. Researchers pursued a novel approach by examining the genetic overlap between TRS and Body Mass Index (BMI). This analysis uncovered two novel genetic loci—MAP2K1 and ZDBF2—associated with TRS. These findings offer insights into potential molecular pathways distinguishing TRS from responsive cases, advancing our understanding of the condition's genetic underpinnings. Additionally, leveraging this genetic overlap significantly enhanced the predictive capacity for TRS using genetic data. This study further illuminates the shared genetic mechanisms linking TRS and BMI, unraveling connections between metabolic dysfunctions and responses to antipsychotic treatments, particularly clozapine's superior efficacy. Identifying these genetic associations opens avenues for exploring new therapeutic targets and comprehending the biological basis of TRS and metabolic disturbances.
Access the article here